TG101209
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
TG101209是基于结构设计的小分子，是一种选择性的janus激酶2（Jak2）抑制剂,可有效抑制多发性骨髓瘤(MM)细胞系中的Jak/Stat通路，如含JAK2V617F或MPLW515L/K突变的细胞，其通常分别与真性红细胞增多症（PV）以及原发性骨髓纤维化（PMF）有关。根据多种研究结果显示，在大范围的多发性骨髓瘤细胞系中，TG101209通过抑制pJak2、pStat3和Bcl-xl的表达，诱导pErk和pAkt的过表达，具有剂量和时间依赖性的细胞毒性，这与抑制细胞周期进程和诱导细胞凋亡有关。
参考文献：
Ramakrishnan V, Kimlinger T, Haug J, Timm M, Wellik L, Halling T, Pardanani A, Tefferi A, Rajkumar SV, Kumar S. TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells. Am J Hematol. 2010;85(9):675-686.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 509.67 |
| Cas No. | 936091-14-4 |
| Formula | C26H35N7O2S |
| Synonyms | TG-101209 |
| Solubility | ≥25.5 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH |
| Chemical Name | N-tert-butyl-3-[[5-methyl-2-[4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]benzenesulfonamide |
| SDF | Download SDF |
| Canonical SMILES | CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)N4CCN(CC4)C |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
| Description | TG101209是一种选择性的JAK2抑制剂，其IC50值为6 nM。 | |||||
| 靶点 | Flt3 | RET | JAK3 | |||
| IC50 | 6 nM | 25 nM | 17 nM | 169 nM | ||
质量控制和MSDS
- 批次:
化学结构
相关生物数据
相关生物数据
